Three years survival rate of epithelial ovarian cancer patients in Dr. Kariadi Hospital, Semarang, Central Java
Downloads
Objectives: to determine the association between prognostic factors of ovarian cancer with a 3-years survival rate of epithelial ovarian cancer patients.
Material and Method: Retrospective cohort study was conducted in 90 patients (during 2012) at Dr.Kariadi General Hospital. Kaplan meier, Log rank and Cox regression were used to analyse survival rate and prognostic factors that influence the disease.
Result: Overall 3-years survival rate of epithelial ovarian cancer patients were 58.5% (Kaplan meier). Three-years survival rates were 89.3%, 44,4%, and 35.1% for patients in stage I, stage II, and stage III, respectively, and no patient survive up to 3 years in stage IV. Prognostic factors that associated with 3-years survival rate were stage of the disease, ascites, residual tumor, and type of histopathology {p<0,001; p=0,001; p=0,004; p=0,041, respectively (Log rank test)}, whereas age and size of tumor were not associated. After using multivariate analysis (Cox regression) only stage of the disease was associated with 3-years survival rate of epithelial ovarian cancer patients.
Conclusion: There were an association between stage of the disease, ascites, residual tumor, type of histopathology, and 3-years survival rate of epithelial ovarian cancer patients. Stage of the disease was a prognostic factor that most influence 3-years survival rate of epithelial ovarian cancer patiens in this study.
Rasjidi I. Epidemiologi Kanker pada Wanita. Jakarta: Sagung Seto; 2010. p. 289-349.
Epithelial Ovarian Cancer. Available from http:// www.who.int/entity/selection_medicines/committees/expert/20/applications/EpithelialOvarian.pdf?ua=1. 2014. Accessed 16 Jul 2016.
Estimated Cancer Incidence, Mortality and Prevalence Wordlwide in 2012. Available from http://globocan.iarc.fr/Default.aspx. 2012. Access-ed 10 Jul 2016.
Busmar B. Kanker Ovarium. Dalam: Aziz MF, Andrijono, Saifuddin AB. Onkologi Ginekologi. Jakarta: Yayasan Bina Pustaka Sarwono Prawiro-hardjo; 2006. hal. 468-525.
Rasjidi I. Deteksi Dini dan Pencegahan Kanker pada Wanita. Jakarta: Sagung Seto; 2009. hal. 183-201.
Nurrika D. Analisis Ketahanan Hidup Lima Tahun Pasien Kanker Ovarium Epithelial di Rumah Sakit Kanker Dharmais Jakarta. Tesis. Jakarta: Univer-sitas Indonesia. 2010.
Ovarian Cancer Survival Statistic. Available from http://www.cancerresearchuk.org/health professio-nal/ cancer-statistics/ statistics-by-cancer-type/ ovarian-cancer/survival#heading-Zero. 2014. Accessed 10 Jul 2016.
Grann AF, Mette N, Jan B, Erik SA, Jacob BJ. Survival of patients with ovarian cancer in central and northern Denmark. Clinical Epidemiology. 2011;21(1-3):59-64.
Sriplung H and Prechavittayakul P. Cancer survival in Songkhla, Thailand, dalam Sankarana-rayanan R and R Swaminathan. Cancer survival in Africa, Asia, the Caribbean and Central America. Lyon: International Agency for Research on Cancer. 2011:227-35.
Zarchi MK, Seyed MRM, Nasrollah B, Neda Z, Mahbube Z, Pouria YA, et al. The clinicopatho-logic characteristics and 5-year survival rate of epithelial ovarian cancer in Yazd, Iran. Electronic Physician. 2015;7(6):1399-406.
Bamias A, Sotiropoulou M, Zagouri F, Trachana P, Sakellariou K, Kostouros E, et al. Prognostic evaluation of tumour type and other histopatho-logical characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/ carboplatin chemotherapy: cell type is the most useful prognostic factor. European Journal of Cancer. 2011;48:1476-83.
Fader AN, Java J, Ueda S, Bristow RE, Armstrong DK, Bookman MA, et al. Survival in women with grade 1 serous ovarian carcinoma. Obstetrics & Gynecology. 2013;122(2).
Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F, et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecol Oncol. 2010;119(2):259-64.
Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV. International Journal of Gynecological Cancer. 2012;22(3):380-5.
Lutgendorf SK, Geest KD, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, et al. Social influen-ces on clinical outcomes of patients with ovarian cancer. Journal of Clinical Oncology. 2012;30: 2885-90.
Adrijono. Sinopsis Kanker Ginekologi. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia; 2013. hal. 87-287.
Jihong L. Tumor Ganas Ovarium, dalam Wan Desen. Buku Ajar Onkologi Klinis. Edisi ke-2. Jakarta: Balai Penerbit FKUI; 2011. hal. 517-26.
Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin MC, You SL, et al. Trends in incidence and survi-val outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol. 2013;24(4):342-51.
Trillsch F, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, et al. Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. Journal of Ovarian Research. 2013;6.
1. Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
2. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
3. The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
